Zealand Pharma A/S

Zealand Pharma is a biotechnology company. Co. is engaged in the discovery development and commercialization of peptide-based medicines. Co.'s pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area are ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment.
  • TickerZLDPF
  • ISINDK0060257814
  • ExchangePink OTC Markets
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ZEALAND PHARMA AS reduced its risk exposure resulting in an upgrade to Slightly Positive

ZEALAND PHARMA AS (DK), a company active in the Biotechnology industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 2 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date March 22, 2019, the closing price was DKK 118.60 and its potential was estimated at DKK 124.53.

Oussema Denguir ...
  • Pierre Corby

Zealand Pharma : Publication contained no surprises, abundant newsflow in 2019

>DKK 1.15bn at end-2018 - Zealand Pharma yesterday evening reported its 2018 results, sales, as expected, fell by 72% to DKK 38m following the sale of the licensing rights for Soliqua and Lyxumia to Royalty Pharma in June 2018. Opex increased by 29% to DKK 481m (in line with expectations), reflecting the progress of the company's various clinical programmes for an operating profit of DKK 652.4m, boosted by the one-off sale of rights to its partnership with Sanofi (DKK...

Oussema Denguir ...
  • Pierre Corby

Zealand Pharma : Une publication sans surprises, 2019 riche en newsflow

>1.15 MdDKK de cash à fin 2018 - Zealand Pharma a publié hier après-midi ses résultats de l’année 2018, le CA est comme attendu en recul de 72% à 38 MDKK suite à la cession des droits de licence de Soliqua et Lyxumia à Royalty Pharma en juin dernier. Les Opex progressent de 29% à 481 MDKK (en ligne avec les attentes) traduisant l’avancement des différents programmes cliniques de la société pour un résultat opérationnel de 652.4 MDKK boosté par le one-off de la vente ...

Team Pharma

ODDO : « Biotech 2019 : la visibilité financière avant tout »

Nous actualisons notre hiérarchie sectorielle biotech en ce début d’année 2019 (15 valeurs). Nous préconisons les sociétés avec un newsflow majeur, focalisées sur un domaine thérapeutique porteur et sans risque cash. Ainsi, nous recommandons à l’Achat Cellectis (OC 26 € - Initiation de couverture), Genfit (OC 63 € vs 59 €), Innate Pharma (OC 11.6 € vs 10.9 € - Top pick) et Orphazyme (OC 96 DKK vs 107 DKK), alors que nous devenons plus prudents sur Genkyotex (Alléger vs Achat - OC...

Team Pharma

ODDO : Biotech stocks in 2019: focus on financial visibility

We have reviewed our biotech sector hierarchy at the start of 2019 (15 stocks). We favour companies with major newsflow, a focus on a specific high-growth therapeutic area and a solid cash position. On this basis, we are at Buy on Cellectis (TP € 26 - initiation of coverage), Genfit (TP € 63 vs € 59), Innate Pharma (TP € 11.6 vs € 10.9 - top pick) and Orphazyme (TP DKK 96 vs DKK 107) and have become more cautious on Genkyotex (Reduce vs Buy, TP € 1.0 vs € 3.4) and Neutral on DBV ...

Eric Le Berrigaud

ZEALAND: Disappointing delay for dasiglucagon rescue | BUY | DKK145 vs. DKK162

ZEALAND - BUY | DKK145 vs. DKK162 (+78%) Disappointing delay for dasiglucagon rescue Third-quarter numbers are useless Dasiglucagon rescue hits by a one-year delay The pipeline is nonetheless densifying Adjustment to our FV

A director sold 2,900 shares at 118.414DKK and

A director at Zealand Pharma As sold 2,900 shares at 118.414DKK and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names...

Christophe Chaput ...
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Geoffroy Michalet
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 03/08/2019 Date Performance since listing Date Performance since listing

Sixt Leasing, an independent player in the German vehicle leasing and fleet management market, stands out for its strong momentum in the online retail and fleet management segments and its capacity to handle the diesel risk effectively. These strengths should pave the way for buoyant growth over the coming years (2018-2021e CAGR of +8% for revenue and 15% for pre-tax profit) and a rerating of the stock (target price € 18.1, i.e. 34% upside). We are initiating coverage of the stock wit...

Christophe Chaput ...
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Geoffroy Michalet
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 08/03/2019

Sixt Leasing, acteur indépendant du marché allemand du leasing de véhicules et de gestion de flottes, se distingue par sa forte dynamique sur les segments Online Retail et Fleet Management, ainsi que par sa capacité à gérer efficacement le risque diesel. Ces atouts se traduiront par une croissance soutenue sur les prochaines années (TMVA18-21e CA : +8% ; RCAI : 15%) et par une revalorisation du titre (OC 18.1 €, soit un potentiel de 34%). Nous initions la couverture avec une opinion A...

Aurelien Sivignon ...
  • Emmanuel Matot
  • Hana Maalej
  • Harold De Decker
  • Jeremy Garnier
  • Jerôme Bodin
  • Oussema Denguir
  • Pierre Corby
  • Valentin Pernet

ODDO BHF Small & MIDCAP MORNING NEWS - 19/09/2018

...

Aurelien Sivignon ...
  • Emmanuel Matot
  • Hana Maalej
  • Harold De Decker
  • Jeremy Garnier
  • Jerôme Bodin
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 09/19/2018

...

ZEALAND PHARMA AS reduced its risk exposure resulting in an upgrade to Slightly Positive

ZEALAND PHARMA AS (DK), a company active in the Biotechnology industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 2 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date March 22, 2019, the closing price was DKK 118.60 and its potential was estimated at DKK 124.53.

ValuEngine Rating and Forecast Report for ZEAL

ValuEngine Rating and Forecast Report for ZEAL

ValuEngine Rating and Forecast Report for ZEAL

ValuEngine Rating and Forecast Report for ZEAL

ValuEngine Rating and Forecast Report for ZEAL

ValuEngine Rating and Forecast Report for ZEAL

ValuEngine Rating and Forecast Report for ZEAL

ValuEngine Rating and Forecast Report for ZEAL

ResearchPool Subscriptions

Get the most out of your insights

Get in touch